Table 1.
Upcoming studies of immune checkpoint blockade in cHL
| Disease Setting | Regimen | Target | Phase | Status | Est. Study Completion Date | NCT |
|---|---|---|---|---|---|---|
| Newly Diagnosed, untreated cHL | ||||||
| Newly diagnosed cHL (age <60 with HR features, age >60) | A(B)VD +Nivo | PD-1 | I | Recruiting | 01/2020 | NCT03033914 |
| Early stage, unfavorable risk, no prior treatment. | Nivo + AVD -> IFRT vs. Nivo × 4 cycles -> Nivo + AVD × 2 cycles -> AVD × 2 cycles -> IFRT | PD-1 | II | Recruiting | 12/2020 | NCT03004833 |
| Age>60, ineligible for or declined conventional chemotherapy | Nivo + BV vs BV + Benda vs. BV + dacarbazine vs BV | PD-1 | II | Recruiting | 10/2018 | NCT01716806 |
| Untreated, transplant ineligible | Nivo + BV | PD-1 | II | Recruiting | 05/2024 | NCT02758717 |
| Relapsed/Refractory cHL | ||||||
| Early stage Relapsed or Primary Refractory cHL | Pembro + ISRT | PD-1 | II | Recruiting | 06/2020 | NCT03179917 |
| R/R cHL (No prior BV, IO agent, or transplant) | Nivo + BV | PD-1 | I/II | Recruiting | 05/2020 | NCT02572167 |
| R/R cHL (2nd line only) | Nivo + ICE | PD-1 | II | Recruiting | 04/2019 | NCT03016871 |
| R/R cHL, no prior SCT (allo or auto) | Pembro + ICE | PD-1 | II | Recruiting | 02/2020 | NCT03077828 |
| R/R cHL, prior auto or allo HSCT allowed, BV, and IO agent allowed | Ipi + Nivo + BV vs Ipi + BV vs. Ipi + Nivo + BV | CTLA-4, PD-1 | I | Recruiting | 06/2018 | NCT01896999 |
| R/R cHL (no prior allo-HSCT) | Avelumab | PDL1 | Ib | Recruiting | 09/2017 | NCT02603419 |
| R/R cHL (no prior allo-HSCT) | Ibrutinib + Nivo | PD-1 | II | Recruiting | 05/2020 | NCT02940301 |
| Children/Adolescents/Young Adults (≥1 line of therapy, no prior HSCT) | Nivo + BV, followed by BV+Benda in suboptimal responders (CheckMate 744) | PD-1 | II | Recruiting | 03/2022 | NCT02927769 |
| R/R (after SCT or transplant-ineligible) | ||||||
| R/R cHL (prior auto-HSCT, or transplant-ineligible) | Nivo + BV vs. BV (CheckMate 812) | PD-1 | III | NYO | 04/2024 | NCT03138499 |
| R/R cHL in BV-naive (failed auto-HSCT or transplant ineligible) | Pembro vs. BV (KEYNOTE-204) | PD-1 | III | Recruiting | 12/2019 | NCT02684292 |
| R/R cHL after auto-HSCT and BV, or chemo-refractory with or without prior auto-HSCT) | Pembro | PD | II | Active, not recruiting | 04/2021 | NCT02453594 |
| Post auto-HSCT | Pembro | PD-1 | II | Recruiting | 12/2018 | NCT02362997 |
| R/R HR cHL | Nivo + BV, to start within 30–60 days of auto-HSCT stem cell infusion | PD-1 | II | Recruiting | 04/2019 | NCT03057795 |
| R/R cHL (transplant ineligible) | Pembro + lenalidomide | PD-1 | I | Recruiting | 08/2023 | NCT02875067 |
| R/R cHL with prior auto-HSCT or R/R transplant-ineligible | Nivo + lenalidomide | PD-1 | Ib | Recruiting | 04/2020 | NCT03015896 |
| Relapse after allo-HSCT | Ipi or Nivo | CTLA-4, PD-1 | I | Recruiting | 12/2018 | NCT01822509 |
| Relapse after allo-HSCT | Pembro | PD-1 | I | Recruiting | 02/2020 | NCT02981914 |
Legend: Allo = Allogeneic, AVD = Adriamycin + Vinblastine + Dacarbazine, Benda = Bendamustine, BV = Brentuximab vedotin, Dex = Dexamethasone, Durva = Durvalumab (anti-PDL1), HD = High Dose, HR = High Risk, IFRT = Involved field radiotherapy, ISRT = Involved Site Radiotherapy, IO = immuno-oncology, Ipi = Ipilimumab (anti-CTLA-4), Len = Lenalidomide, MM = Multiple Myeloma, Nivo = Nivolumab (anti-PD-1), NR = Not Reported, NYO = Not Yet Open, Pembro = Pembrolizumab (anti-PD-1), Pom = Pomalidomide, SCT = Stem Cell Transplant, Treme = Tremelimumab (anti-CTLA-4). Status as reported by http://clinicaltrials.gov, accessed 6/12/2017